The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...

With Novo Nordisk’s blockbuster drugs Wegovy and Ozempic back in stock, copycat versions of semaglutide are no longer allowed ...

Makers of copycat versions of Novo Nordisk's (NVO) weight-loss drug semaglutide, also known as Ozempic and Wegovy, are suing ...

A group representing compounding pharmacies has filed a lawsuit against the US Food and Drug Administration, arguing that the ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

The FDA recently removed semaglutide from its drug shortage list, which has not been considered commercially available since ...

Compounding pharmacies aren’t surrendering their ability to create cheaper knockoff versions of Eli Lilly and Novo Nordisk’s ...

On February 21, 2025, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order determining that the semaglutide ...

The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...

Last week, the US Food and Drug Administration (FDA) announced the end of a years-long shortage of semaglutide injection products — a ...

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.

Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed ...